文献速递免疫规划卫生政策与健康促进

美国19-45岁成人人乳头瘤病毒疫苗接种率:基于2017年全国健康访谈调查的分析

Human Papillomavirus Vaccination Prevalence Among Adults Aged 19-45 Years: An Analysis of the 2017 National Health Interview Survey.
PubMed 文献 · Am J Prev Med · 2020-11-05

该研究基于2017年美国全国健康访谈调查的9744名19-45岁成人数据,估计在2018年FDA扩大许可和2019年ACIP推荐之前的HPV疫苗接种率。结果显示19-26岁年轻成人至少接种1剂的比例为36.3%(女性51.5%,男性21.2%),27-45岁中年成人为9.7%(女性15.8%,男性3.2%)。在中年成人和年轻男性中,年龄与接种呈负相关。全部接种者中26.6%首次接种在成年期。

要点

  • 2017年美国19-26岁成人HPV疫苗至少1剂接种率为36.3%,27-45岁仅9.7%。
  • 女性接种率高于男性:年轻成人女性51.5% vs 男性21.2%,中年女性15.8% vs 男性3.2%。
  • 中年成人和年轻男性中,年龄增长与接种几率降低独立相关。

核心结论

  • 在2018年FDA扩大许可和2019年ACIP推荐之前,美国19-45岁成人HPV疫苗接种率较低,尤其是27-45岁中年成人和男性。
  • 数据强调继续为11-12岁青少年接种HPV疫苗的必要性,因为少数成人已接种。

研究设计与样本

  • 研究采用2017年美国全国健康访谈调查(NHIS)数据,最终样本包括9744名19-45岁成人(2522名年轻成人19-26岁,7222名中年成人27-45岁)。
  • 主要结局为是否接种至少1剂HPV疫苗以及是否在成年期接种,分析中纳入人口学特征和医疗保健因素作为协变量。

主要发现

  • 年轻成人至少接种1剂HPV疫苗的人群估计比例为36.3%(女性51.5%,男性21.2%;p<0.001)。
  • 中年成人至少接种1剂HPV疫苗的比例为9.7%(女性15.8%,男性3.2%;p<0.001)。
  • 在最佳拟合模型中,中年成人中年龄与接种负相关(女性:OR=0.84,95%CI=0.81,0.86;男性:OR=0.86,95%CI=0.82,0.90),年轻男性中亦负相关(OR=0.79,95%CI=0.71,0.88)。
  • 全部19-45岁接种者中,26.6%(95%CI=23.9,29.4)首次接种发生在成年期。

临床怎么用

  • 研究结果可作为监测美国成人HPV疫苗接种覆盖率变化的基线,尤其关注27-45岁人群和男性。
  • 应继续强调11-12岁青少年常规接种HPV疫苗,以降低成年后接种需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In 2018, the U.S. Food and Drug Administration extended the licensure for human papillomavirus vaccination to include everyone aged 27-45 years. In 2019, the Advisory Committee on Immunization Practices issued a recommendation that adults aged 27-45 years and their providers engage in shared clinical decision making about human papillomavirus vaccination. In addition, in 2019, the Advisory Committee on Immunization Practices reiterated that all previously unvaccinated individuals receive catch-up vaccination through age 26 years. This study estimates the pre-recommendation prevalence of human papillomavirus vaccination and factors associated with vaccination in 2 age groups (19-26 years [young adults] and 27-45 years [mid-adults]), forming a baseline to monitor future coverage among U.S. adults. METHODS: The final sample included 9,744 individuals (2,522 young adults and 7,222 mid-adults) who participated in the 2017 National Health Interview Survey. The main outcomes were receipt of 1 or more human papillomavirus vaccination and whether the participant had been vaccinated as an adult. Demographic characteristics and healthcare factors were included as covariates in statistical analyses. RESULTS: Population estimate of receiving 1 or more human papillomavirus vaccine doses among young adults was 36.3% (female: 51.5%, male: 21.2%; p<0.001) and 9.7% for mid-adults (females: 15.8%, males: 3.2%; p<0.001). In the best-fit model, age was inversely associated with vaccination for mid-adults (female: OR=0.84, 95% CI=0.81, 0.86; male: OR=0.86; 95% CI=0.82, 0.90) and male young adults (OR=0.79, 95% CI=0.71, 0.88). Of the entire vaccinated sample aged 19-45 years, 26.6% had received their first vaccination as an adult (95% CI=23.9, 29.4). CONCLUSIONS: These data emphasize the continued need for vaccinating adolescents aged 11-12 years given that few adults were vaccinated against human papillomavirus.

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Kasting ML, Giuliano AR, Christy SM, et al. Human Papillomavirus Vaccination Prevalence Among Adults Aged 19-45 Years: An Analysis of the 2017 National Health Interview Survey. Am J Prev Med. 2020. PMID: 33160800. doi:10.1016/j.amepre.2020.05.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。